Drug intelligence / Profile preview

AK-321

Development stage: Preclinical
Lead developer: Akanocure
Modality: Small Molecules

Overview

AK-321 is a small molecule targeted protein-protein interaction modulator developed by Akanocure Pharmaceuticals. It is designed to treat hard-to-treat and metastatic cancers by inhibiting the interaction between actin microfilaments and microtubules. Additionally, the drug interacts with cytoskeletal-associated proteins and Focal Adhesion Kinase (FAK). By targeting the cytoskeleton/adhesion pathway that cancer cells utilize for migration, AK-321 aims to limit the spread of metastatic tumors. The compound has demonstrated picomolar potency in preclinical studies and is being developed in collaboration with the National Cancer Institute (NCI) to progress toward clinical trials.

Targets

TUBB (Tubulin (alpha and beta subunits))Actin filament proteinsFAK (Focal adhesion kinase)

Beyond the preview

Go deeper on AK-321.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK-321.

Explore the full profile